Merck, Codexis renew enzyme production pact; J&J recalls a lot of Imodium; Ranbaxy relaunches skin product;

> Six years in and Merck ($MRK) likes so much its partnership with Codexis ($CDXS), which has been developing enzymes for Merck's manufacturing processes, that the two have signed another three-year deal. Release

> Ranbaxy Laboratories is re-launching its skincare drug Sotret, which was pulled from the market when the FDA banned 30 drugs that were tied to two plants in India, but this time around it will be manufactured by its partner in the project, Cipher Pharmaceuticals. Story

> Baxter International ($BAX) facilities in Halle and Bielefeld in Germany have received certification for safe handling of compounds. Item

> Johnson & Johnson's ($JNJ) McNeil Consumer Healthcare, which has gotten accustomed to recalling products in large quantities, is retrieving a lot of Imodium, nearly 54,000 packages. Story

> AlpVision and Nolato Medical are working together on a new packaging that can use an iPhone to protect against counterfeiting. Item

Suggested Articles

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

Boehringer Ingelheim is investing $50 million in an animal health plant in Puerto Rico, adding 105 jobs.

Teva will begin producing chemo drug vincristine in the U.S. but has resisted the idea that its withdrawal from the market led to a shortage.